Alternative Breast Cancer Treatment Advanced inpatient care at CMN Hospital.
Treatment is provided within CMN Hospital, a licensed full-service general hospital where physician evaluations, therapies, laboratory services, meals, and daily care are coordinated in one inpatient setting.CMN Hospital provides advanced inpatient care for women with breast cancer through Dr. Edgar Payán’s 28-day Advanced Cancer Treatment program. Each patient is evaluated individually based on diagnosis, pathology, receptor status, imaging, laboratory findings, previous treatments, current condition, and overall health.
Understanding Breast Cancer
Breast cancer develops when abnormal cells in the breast grow in an uncontrolled way. It may begin in the milk ducts, lobules, or other breast tissue and can sometimes spread to lymph nodes, bones, liver, lungs, brain, or other areas of the body. Breast cancer is not one single disease. Tumors may differ by location, stage, hormone receptor status, HER2 status, grade, genetic features, prior treatment response, and whether the cancer is newly diagnosed, recurrent, or metastatic.
Because breast cancer can behave differently from one patient to another, treatment discussions should be based on a careful review of medical records, pathology, imaging, receptor testing, previous treatments, and the patient’s overall medical condition.
Types of Breast Cancer
Breast cancer may be described by where it begins, whether it has spread, and the biologic features found on pathology testing.
Invasive Ductal Carcinoma
The most common type of invasive breast cancer, beginning in the milk ducts and spreading into nearby breast tissue.
Invasive Lobular Carcinoma
A type of breast cancer that begins in the lobules and may be more difficult to detect on routine imaging.
DCIS
Ductal carcinoma in situ is a non-invasive breast cancer confined to the milk ducts.
LCIS
Lobular carcinoma in situ is not invasive cancer, but it may indicate an increased risk of developing breast cancer.
Hormone Receptor and HER2 Status
Breast cancer is also classified by hormone receptor and HER2 testing. These results help physicians understand the biology of the tumor and are important when reviewing conventional treatment options.
ER+/PR+, HER2-Negative
Hormone receptor-positive breast cancer may respond to treatments that block estrogen or progesterone activity.
ER+/PR+, HER2-Positive
This subtype is both hormone receptor-positive and HER2-positive, which may influence conventional treatment planning.
HER2-Positive, HR-Negative
This breast cancer is HER2-positive without estrogen or progesterone receptor involvement.
Triple-Negative
Triple-negative breast cancer does not express estrogen receptors, progesterone receptors, or HER2.
Triple-Positive
Triple-positive breast cancer is positive for estrogen receptors, progesterone receptors, and HER2.
Recurrent or Metastatic
Breast cancer may return after treatment or spread to distant areas of the body, requiring careful review of prior care and current findings.
Signs and Symptoms
- A lump or thickened area in the breast or underarm
- Changes in breast size, shape, or contour
- Skin dimpling, redness, scaling, or thickening
- Nipple inversion or nipple changes
- Nipple discharge, including bloody discharge
- Breast swelling, tenderness, or pain
- Enlarged lymph nodes near the breast or underarm
How Breast Cancer Is Diagnosed
Diagnosis and treatment planning may involve several tests to confirm the breast cancer type, stage, receptor status, and extent of disease.
- Mammography
- Breast ultrasound
- Breast MRI
- Core needle biopsy or surgical biopsy
- Pathology review
- Estrogen receptor testing
- Progesterone receptor testing
- HER2 testing
- Ki-67 or tumor proliferation testing when indicated
- Genetic testing, including BRCA1 and BRCA2 when appropriate
- CT, PET, bone scan, or other imaging when metastatic disease is suspected
Breast Cancer Stages
Stage 0
Non-invasive breast cancer, such as DCIS, confined to the milk ducts.
Stage I
Early breast cancer that is small and may or may not involve nearby lymph nodes.
Stage II
Breast cancer that may be larger or involve nearby lymph nodes.
Stage III
Locally advanced breast cancer involving more extensive lymph node or nearby tissue involvement.
Stage IV
Metastatic breast cancer that has spread to distant areas of the body.
Conventional Treatment Options
Conventional treatment recommendations vary based on cancer type, stage, receptor status, prior treatments, genetic findings, and the patient’s overall health.
- Lumpectomy or breast-conserving surgery
- Mastectomy
- Sentinel lymph node biopsy
- Axillary lymph node dissection
- Chemotherapy
- Radiation therapy
- Hormone therapy
- HER2-targeted therapy
- Immunotherapy for selected patients
- Targeted therapy based on tumor features
- Breast reconstruction
- Clinical trials when appropriate
Advanced and Recurrent Breast Cancer
Many women who contact CMN Hospital have already received surgery, chemotherapy, radiation therapy, hormone therapy, HER2-targeted therapy, immunotherapy, or other treatments before seeking additional options. Others may be living with recurrent, persistent, locally advanced, or metastatic breast cancer.
Because breast cancer can change over time and may respond differently after prior treatment, Dr. Payán reviews each patient’s pathology, receptor status, imaging, laboratory findings, treatment history, current condition, and overall health before discussing whether CMN Hospital’s program may be appropriate.
Individualized Physician Review
At CMN Hospital, every patient is evaluated individually. Dr. Edgar Payán, General Hospital Director and Medical Director of CMN Hospital, personally reviews each patient’s medical records, pathology reports, receptor testing, imaging studies, laboratory findings, previous treatments, current health status, and other relevant clinical information.
Following this comprehensive review, Dr. Payán meets personally with each patient during a consultation to discuss the findings, answer questions, determine whether CMN Hospital’s 28-day inpatient Advanced Cancer Treatment program may be appropriate, and explain the treatment options available based on the patient’s individual medical evaluation.
Why Women Choose CMN Hospital
Women who come to CMN Hospital for breast cancer treatment are often looking for a more organized and comprehensive approach to their care. Many arrive physically exhausted, emotionally overwhelmed, and tired of managing appointments, treatment decisions, travel, and uncertainty while carrying the weight of a breast cancer diagnosis.
Inside the 28-day inpatient program, care is brought together within one hospital environment. Therapies, laboratory services, meals, physician evaluations, and daily care are coordinated around the patient while she remains within the comfort and privacy of her suite throughout most of her stay.
If a patient proceeds with treatment, Dr. Payán oversees her care throughout the inpatient stay and continues to personally monitor her progress through scheduled monthly Zoom follow-up appointments after discharge.
Hormone-Positive Breast Cancer
Hormone-positive breast cancers, including estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast cancer, are among the most common breast cancer diagnoses treated at CMN Hospital. Many women initially undergo chemotherapy, radiation, surgery, hormone-blocking medications, immunotherapy, or targeted therapies before eventually searching for additional options after recurrence, progression, or physically difficult recoveries.
Over the years, more women facing advanced-stage and recurrent breast cancer continued arriving at CMN Hospital after already undergoing extensive conventional treatment. As a result, Dr. Edgar Payán’s inpatient experience naturally evolved around helping women whose bodies often felt physically exhausted, nutritionally depleted, inflamed, and weakened following prior therapies.
Inside the 28-day inpatient program, care focuses not only on treatment planning, but also on helping the body regain strength, nutritional stability, immune support, and recovery support throughout the patient’s stay. Therapies are individualized based on diagnosis, imaging, pathology, present condition, and prior treatment history.
Research involving autologous hematopoietic stem cell transplantation in advanced breast cancer has continued for decades, particularly in women with metastatic and recurrent disease following chemotherapy. Stanford University researchers published long-term findings involving women with stage IV breast cancer treated with high-dose chemotherapy followed by transplantation using highly purified autologous hematopoietic stem cells.
The Stanford researchers reported favorable long-term survival outcomes within portions of the study population and concluded that purified autologous stem-cell-supported treatment strategies in advanced breast cancer warranted continued scientific attention. At CMN Hospital, Dr. Edgar Payán incorporates autologous bone marrow stem cell therapy within individualized inpatient treatment planning for some breast cancer patients as part of a broader program focused on recovery support, immune function, nutritional stability, and helping the body regain strength following prior treatments.
Triple-Positive Breast Cancer
Triple-positive breast cancer means the cancer tests positive for estrogen receptors, progesterone receptors, and HER2. This is important because triple-positive breast cancer involves both hormone receptor activity and HER2 activity. HER2 is a protein involved in cell growth, and HER2-targeted therapies are designed to address the HER2-positive part of the diagnosis.
Many women with HER2-positive or triple-positive breast cancer ask whether they need to stop HER2-targeted therapy before coming to CMN Hospital. Dr. Edgar Payán does not ask patients to discontinue HER2-targeted therapy. He understands that HER2-targeted treatment can be an important part of care for HER2-positive breast cancer, just as other targeted medications are used to address specific findings in other health conditions.
For this reason, integration can be valuable. When appropriate, HER2-targeted therapy may continue to address the HER2-positive part of the diagnosis while Dr. Payán also reviews the hormone-positive part of the cancer, the patient’s prior treatment history, present health condition, nutritional status, immune function, and recovery needs within the 28-day inpatient program.
Because triple-positive breast cancer has more than one important biological factor, Dr. Payán looks carefully at the full picture before determining how care will be approached. Pathology, imaging, medical history, prior treatment, current condition, and patient safety are all reviewed so treatment planning is individualized and medically thoughtful.
Triple Negative Breast Cancer Research
Triple Negative Breast Cancer (TNBC) continues to be one of the most difficult forms of breast cancer to treat because it does not respond to hormone-blocking therapies commonly used in estrogen receptor-positive or progesterone receptor-positive breast cancers. Researchers continue searching for therapies that may help target aggressive TNBC cellular behavior more effectively.
Published laboratory research involving scorpion venom compounds and chlorotoxin has shown growing scientific interest in how venom-derived peptides may interact with breast cancer cells, including Triple Negative Breast Cancer cell lines. Researchers have studied possible effects involving apoptosis, cellular signaling, migration, invasion pathways, and tumor cell viability.
A study published within the National Institutes of Health (NIH) database reported that Rhopalurus junceus scorpion venom demonstrated significant reduction in breast cancer cell viability and induced apoptosis activity within Triple Negative Breast Cancer laboratory cell models. Additional reviews discussing chlorotoxin and venom-derived peptides have examined their interaction with pathways involving TNBC cellular migration and invasion.
Researchers have also studied chlorotoxin because of its ability to bind to certain proteins and enzymes overexpressed in aggressive tumors. Published reviews have discussed possible effects involving MMP-2 pathways, tumor invasion behavior, and metastatic signaling mechanisms connected to breast cancer progression.
At CMN Hospital, Dr. Edgar Payán incorporates blue scorpion venom within individualized treatment planning for some breast cancer patients as part of a broader inpatient program that may also include dendritic cell therapy, autologous bone marrow stem cell therapy, IV therapies, laboratory monitoring, nutritional support, and additional therapies selected based upon the patient’s diagnosis, condition, and treatment history.
Scientific References
Díaz-García et al. — Rhopalurus junceus scorpion venom induces apoptosis in breast cancer cells and reduced cell viability in Triple Negative Breast Cancer models.
Kwon et al. — Systematic review examining anticancer effects and mechanisms of scorpion venom and chlorotoxin-related peptides in breast cancer cell lines including TNBC and hormone-positive breast cancer.
Published research involving chlorotoxin has also examined interactions involving MMP-2 signaling, tumor migration pathways, and targeted tumor-binding mechanisms in aggressive cancers.